All Comments by

  1. Robert Moir on Crystal structure of the amyloid-β p3 fragment provides a model for oligomer formation in Alzheimer's disease.
  2. Helen Cunningham on Miami: Is Human Amyloid Imaging Ready for Clinical Trials?
  3. Jose Joaquin Merino on Genetics of FTD: New Gene, PGRN Variety, and a Bit of FUS
  4. Carlo Condello on CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.
  5. Kathleen Zahs on Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.
  6. Scott Small on Exercise training increases size of hippocampus and improves memory.
  7. Bradley Hyman on Seeing Is Believing—Plaque Growth Is Slow, Tapers With Age
  8. Brian O’Nuallain on Conformational conversion during amyloid formation at atomic resolution.
  9. Wai-Tong Chien on Physical activity predicts gray matter volume in late adulthood: the Cardiovascular Health Study.
  10. Mathias Jucker on Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis.
  11. Daryl Bosco on Decreased stability and increased formation of soluble aggregates by immature superoxide dismutase do not account for disease severity in ALS.
  12. Terrence Town on CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice.
  13. Donna M. Wilcock on CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice.
  14. Brad Friedman on TDP-43 Turns Itself Off, Inclusions a False Lead
  15. Takaomi Saido on What was lost in translation in the DHA trial is whom you should intend to treat.